Get started
Award

Progression of antimicrobial therapy against antimicrobial resistance innovated by maximized therapeutic effect of beta-lactams.

Description: 薬剤耐性菌（AMR）感染症は死亡率が高く、人類の存亡をかけた重大懸念事項である。この課題に対して、AMR感染症であろうと抗菌薬濃度を最大殺菌効果に必要なレベルまで引き上げることで、AMR感染症を治療できる可能性を見出してきた。そこで本研究の目的は、患者それぞれで抗菌薬濃度を測定し投与量調節を行う（ベイズ推定に基づいたTDM）ことで、AMR感染症に対する治療成績および安全性を評価することである。
Amount: ¥4,160,000
Funding type: fellowship
Funder scheme: Grant-in-Aid for Early-Career Scientists
Start date: 2020-04-01
End date: 2024-03-31
Investigator: Kazutaka Oda (lead)
Institution: Kumamoto University
Field: Medicine
Funded outputs count: 15
Funder award ID: 20K17467
OpenAlex ID: G6186952198
Quantifying the Impact of Discrepancies Between Actual and Recorded Blood Sampling Times on Bayesian Forecasting for Area Under the Concentration–Time Curve Estimation of Vancomycin
2026 · Tomoyuki Yamada, Kazutaka Oda, et al. · Basic & Clinical Pharmacology & Toxicology
Empirical dosage determination of vancomycin for a target area under the concentration‐time curve of 400 μg·h/mL in the first 24 h: A prospective multicenter observational study with rich sampling
2025 · Kazutaka Oda, Yoko Hiyama, et al. · British Journal of Clinical Pharmacology · 3
PDF
Model‐informed precision dosing of vancomycin for rapid achievement of target area under the concentration‐time curve: A simulation study
2023 · Kazutaka Oda, Tomoyuki Yamada, et al. · Clinical and Translational Science · 23
PDF
Dose Individualization of Cefepime for Febrile Neutropenia in Patients With Lymphoma or Multiple Myeloma: Implications for Therapeutic Drug Monitoring
2023 · Kazutaka Oda, Ayami Yamaguchi, et al. · Therapeutic Drug Monitoring · 2
Model-Informed Precision Dosing of Vancomycin in Adult Patients Undergoing Hemodialysis
2023 · Kazutaka Oda, Hirofumi Jono, et al. · Antimicrobial Agents and Chemotherapy · 14
PDF
Bayesian prediction-based individualized dosing of anti-methicillin-resistant Staphylococcus aureus treatment: Recent advancements and prospects in therapeutic drug monitoring
2023 · Kazutaka Oda, Hideyuki Saito, et al. · Pharmacology & Therapeutics · 18
Population Pharmacokinetics and AUC-Guided Dosing of Tobramycin in the Treatment of Infections Caused by Glucose-Nonfermenting Gram-Negative Bacteria
2023 · Yumi Hashiguchi, Naoya Matsumoto, et al. · Clinical Therapeutics · 8
PDF
Model‐informed precision dosing of teicoplanin for the rapid achievement of the target area under the concentration‐time curve: A simulation study
2023 · Kazutaka Oda, Tomoyuki Yamada, et al. · Clinical and Translational Science · 3
Clinical Practice Guideline for the Therapeutic Drug Monitoring of Voriconazole in Non-Asian and Asian Adult Patients: Consensus Review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring
2022 · Yoshio Takesue, Yuki Hanai, et al. · Clinical Therapeutics · 91
Development of Novel Dosing Strategy According to the Area under the Concentration-Time Curve for Vancomycin
2022 · Kazutaka Oda · YAKUGAKU ZASSHI · 3
PDF
Current Aspects of Pediatric Pharmacokinetics and Pharmacodynamics of Antimicrobials in Japan: Importance of the Promotion of Population PK/PD Analysis
2022 · Kensuke Shoji, Jumpei Saito, et al. · The Pediatric Infectious Disease Journal
Probability of target attainment of oral antimicrobials for Escherichia coli and Klebsiella pneumoniae based on Monte Carlo simulations
2022 · Tomoyuki Yamada, Kenta Minami, et al. · Diagnostic Microbiology and Infectious Disease · 7
PDF
Clinical evaluation of an authorized medical equipment based on high performance liquid chromatography for measurement of serum voriconazole concentration
2021 · Kazutaka Oda, Shota Uchino, et al. · Journal of Pharmaceutical Health Care and Sciences · 10
PDF
Lowered Risk of Nephrotoxicity through Intervention against the Combined Use of Vancomycin and Tazobactam/Piperacillin: A Retrospective Cohort Study
2021 · Kazutaka Oda, Yumi Hashiguchi, et al. · Microbiology Spectrum · 9
Clinical evaluation of cefotiam in the treatment of bacteremia caused by Escherichia coli, Klebsiella species, and Proteus mirabilis: A retrospective study
2020 · Yumi Hashiguchi, Kazutaka Oda, et al. · Journal of Infection and Chemotherapy · 6